3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
9
Unspecified Adult Solid Tumor, Protocol Specific
2
Sarcoma
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostatic Diseases
1
Pancreatic Neoplasms
1
Pain
1
Non-squamous Non-small Cell Lung Cancer
1
Neoplasms, Glandular and Epithelial
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Genital Neoplasms, Male
1
Genital Diseases, Male
1
Gallbladder Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms, Male
1
Bile Duct Neoplasms
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
pembrolizumab
8
Paclitaxel
8
Carboplatin
6
Megestrol Acetate
4
niraparib
3
Cisplatin
3
tislelizumab
2
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
2
rucaparib
2
olaparib
2
iso-sulfan blue
2
copanlisib
2
Taxes
2
Surveys and Questionnaires
2
Nivolumab
2
Lymph Node Excision
2
Indocyanine Green
2
Fulvestrant
2
Filgrastim
2
Doxorubicin
2
Docetaxel
2
tremelimumab
1
spartalizumab
1
sonidegib
1
ribociclib
1
rebastinib
1
pemigatinib
1
nicotinamide-beta-riboside
1
lenvatinib
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Endometrial Neoplasms
×
ixabepilone
×
Clear all
NCT00883116
2017-03-09
IXAMPLE2
R-Pharm
Phase 3
Terminated
551 enrolled
13 charts